deltatrials
Recruiting PHASE1 INTERVENTIONAL 8-arm NCT06999187

A Study of DR-0202 in Patients With Locally Advanced or Metastatic, Relapsed or Refractory Carcinomas

A Phase 1a/1b, Multicenter, Open-label, Dose Escalation/Expansion, Multiple-dose Study to Evaluate the Safety and Activity of DR-0202 in Patients With Locally Advanced or Metastatic, Relapsed or Refractory Carcinomas

Sponsor: Dren Bio

Conditions Castrate Resistant Prostate Cancer Cervical Cancer Endometrial Cancer Gastric Cancer Gastroesophageal-junction Cancer HER2-negative Breast Cancer Head-and-neck Squamous Cell Carcinoma Non Small Cell Lung Cancer Ovarian Cancer Pancreatic Ductal Adenocarcinoma Triple Negative Breast Cancer Urothelial Carcinoma
Interventions DR-0202
Updated 5 times since 2025 Last updated: Jan 5, 2026 Started: Jun 3, 2025 Primary completion: Jul 31, 2027 Completion: Dec 31, 2027
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE1 clinical study on Castrate Resistant Prostate Cancer and Cervical Cancer, this trial is actively recruiting participants. The trial is conducted by Dren Bio and has accumulated 5 data snapshots since 2025. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.

Status Flow

~Jun 2025 – ~Jul 2025 · 30 days · monthly snapshot~Jul 2025 – ~Aug 2025 · 31 days · monthly snapshot~Aug 2025 – ~Sep 2025 · 31 days · monthly snapshot~Sep 2025 – ~Feb 2026 · 5 months · monthly snapshotRecruiting~Feb 2026 – present · 6 months · monthly snapshotRecruiting

Change History

5 versions recorded

  1. Feb 2026 — Present [monthly]

    Recruiting PHASE1

  2. Sep 2025 — Feb 2026 [monthly]

    Recruiting PHASE1

  3. Aug 2025 — Sep 2025 [monthly]

    Recruiting PHASE1

  4. Jul 2025 — Aug 2025 [monthly]

    Recruiting PHASE1

    Status: Not Yet Recruiting → Recruiting

  5. Jun 2025 — Jul 2025 [monthly]

    Not Yet Recruiting PHASE1

    First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Dren Bio
Data source: Dren Bio

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations